39.59 0.00 (0.00%)
After hours: 4:51PM EDT
|Bid||39.30 x 4000|
|Ask||39.70 x 2200|
|Day's Range||39.03 - 39.76|
|52 Week Range||31.99 - 40.16|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||37.53|
|Forward Dividend & Yield||1.40 (3.59%)|
|1y Target Est||41.66|
PLC has struck a deal with a French biotechnology firm to add a promising cancer drug to its pipeline, boosting its focus on oncology as part of broader strategy to double sales in the next five years. AstraZeneca will also gain access to a second cancer drug in Innate’s pipeline, dubbed IPH5201, and the right to license four to-be-agreed medicines in early-stage development at the French company. AstraZeneca will also take a 9.8% stake in Innate Pharma.
Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.
LONDON/PARIS (Reuters) - AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday's agreement is a coup for Innate - run by former AstraZeneca executive Mondher Mahjoubi - which gains rights to sell AstraZeneca's newly approved rare blood cancer drug Lumoxiti as its first commercial product. AstraZeneca's purchase of 6.26 million new shares in Innate at a price of 10 euros each, or double the market rate, marks a vote of confidence in the cancer immunotherapy specialist and Innate shares jumped 29 percent on the deal news.
LONDON/PARIS, Oct 23 (Reuters) - AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday's agreement is a coup for Innate - run by former AstraZeneca executive Mondher Mahjoubi - which gains rights to sell AstraZeneca's newly approved rare blood cancer drug Lumoxiti as its first commercial product.
As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017.
35 scientific data presentations and publications, including new evidence for LOKELMA™ in hyperkalemia and FARXIGA® on renal endpoi
60% of patients receiving LYNPARZA remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy
Let's check out the Yahoo Finance charts of the day. AstraZeneca (AZN ): Shares are down in early trade, at around .61%. The drugmaker has a wide-ranging deal with French biotech company Innate Pharma, which includes the British group buying a 9.8 percent stake in the biotech company. Harley-Davidson (HOG ): Shares down here, 4.0%. The motorcycle company beat estimates by 15 cents a share, with a 68 cent per share profit. They beat on the top line with improved European sales and a full-year motorcycle shipment forecast. Johnson and Johnson (JNJ): Shares down here, around .74%. The healthcare company is offering 2.1 billion for the portion of Japanese cosmetic firm, Ci:z Holdings, that it doesn't already own. J&J had held 19.9 percent of the outstanding shares. For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance